FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

[
FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
[og_img]
https://www.investing.com/news/press-releases/fda-approves-the-avmapki-fakzynja-combination-therapy-as-the-firstever-treatment-for-adult-patients-with-krasmutated-recurrent-lowgrade-serous-ovarian-cancer-93CH-4033899


Investing.com